Use multiplexable genome editing in combination with extensive knowledge in transplantation immunology to create immunologically privileged allogenic cells and xenogeneic organs for use as therapies to treat cancer, organ failure and other important medical conditions
NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.